Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2000

View Archived Issues

AstraZeneca and Cellomics collaborate on accelerating drug discovery

EntreMed establishes angiogenesis collaboration with Children's Hospital of Boston

ArQule and Monsanto extend and expand agreement

Genotropin delivery device now available for long-term replacement therapy in GHD

NCI to initiate phase III trial of Neovastat in the U.S. and Canada

Immunomedics' bispecific fusion proteins covered by U.S. patent

Recently issued patent covers Neurogens new selective dopamine D4 ligands

Novel anticonvulsants in development at SmithKline Beecham

Selective GABA-A ligands synthesized at MS&D for use particularly as nonsedating anxiolytics

Yoshitomi announces upcoming name change

Phase I results support efficacy of rhVEGF in producing therapeutic angiogenesis

Pfizer presents new series of JAK3 inhibitors for autoimmune diseases

Thienodipyridines useful for inflammatory and immune disorders designed at Takeda

New inhibitors of cGMP-PDE in development at BMS for ED and cardiovascular conditions

Takeda reveals new GnRH antagonists in recently issued patent

SB-269970: a potent and selective 5-HT7 receptor antagonist ligand

StemCells reports first direct isolation of human brain stem cells

New findings enhance validity of preclinical models for evaluating LHRH peptide conjugates

DuPont Pharma to acquire Canadian rights to Mallinckrodt's nuclear medicine products

Glaxo Wellcome and NeuroSearch to develop NS-2389 for treatment of depression

Cellegy expands Anogesic clinical trial for reduction of pain in hemorrhoidectomy

Pharmacia & Upjohn launches Aromasin breast cancer therapy in the U.S.

Georgetown University to study Magainin's squalamine for diabetic retinopathy

New treatment for CF now available in U.K. pharmacies

Antiinflammatory factor identified in glucocorticoid-treated human monocytes

Boehringer Ingelheim brings new angiotensin II antagonist to market in U.K.

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...